Study of Dasatinib (BMS-354825) in Subjects With Chronic Phase or Advanced Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant to or Intolerant of Imatinib Mesylate
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Leukemia
Both
Leukemia
Trial Information
Study of Dasatinib (BMS-354825) in Subjects With Chronic Phase or Advanced Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant to or Intolerant of Imatinib Mesylate
Inclusion Criteria:
- Clinical diagnosis of CML or Ph+ ALL who have primary or acquired resistance to or
intolerance of imatinib mesylate
- ECOG performance status score 0 - 2
- Adequate hepatic, renal function
Type of Study:
Expanded Access
Study Design:
N/A
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb, Korea
Authority:
Korea: Food and Drug Administration
Study ID:
CA180-109
NCT ID:
NCT00454753
Start Date:
May 2007
Completion Date:
Related Keywords:
- Leukemia
- Myeloid, Chronic
- Lymphocytic, Acute
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Philadelphia Chromosome
Name | Location |
|---|
